STAT5A and mature T-cell and NK-cell non-Hodgkin lymphoma: This is of therapeutic relevance since PTCL patients frequently exhibit transcriptional signatures associated to the activation of other STAT members like STAT1 and STAT5 (ref. 4), and STAT5B activating mutations have been described in PTCL subtypes28.